Genscript Biotech (HK:1548) has released an update.
Genscript Biotech’s subsidiary, Legend Biotech, reported approximately US$186 million in net sales for CARVYKTI® in Q2 2024, as filed with the U.S. SEC. These preliminary results, under a collaboration with Janssen Biotech, have not been independently verified by Legend or Genscript Biotech. Investors are cautioned to consider the inherent risks and uncertainties in such forward-looking statements when dealing with the company’s securities.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
